From the Conference Q/A -Old Tollovir data to b
Post# of 30067
(Total Views: 320)
Posted On: 07/09/2021 1:34:37 AM
.jpg)
From the Conference Q/A
-Old Tollovir data to be put out in next couple months
-Tollovir/Tollotest P2 recruitment in Israel was slow, but has picked up, Data Q3 or early Q4
-Start India Trial in August, finish early Q4, broader data set hospitalized and non-hospitalized
-Robust Phase 3 to start in Q4
-EUA's could follow quickly
-Todos has engaged NDA partners to take a crack at the Antiviral Task Force $3.2B, but need to file IND in US
-Working to get Videssa back in lab in Q4, which will enable commercialization
-May conduct additional Videssa studies in younger women
-Separate Crowdfunding action for a separate Tollovid entity
-Investor Relations firms are being engaged.
-Active discussions with Nasdaq. Strong support from existing Institutional investors
-Revenue coming in on Provista PCR testing, expect Q3
-Debt will convert to equity at uplist
Same old blah blah blah company not focused, investors just don't get how much we have going on.
-Old Tollovir data to be put out in next couple months
-Tollovir/Tollotest P2 recruitment in Israel was slow, but has picked up, Data Q3 or early Q4
-Start India Trial in August, finish early Q4, broader data set hospitalized and non-hospitalized
-Robust Phase 3 to start in Q4
-EUA's could follow quickly
-Todos has engaged NDA partners to take a crack at the Antiviral Task Force $3.2B, but need to file IND in US
-Working to get Videssa back in lab in Q4, which will enable commercialization
-May conduct additional Videssa studies in younger women
-Separate Crowdfunding action for a separate Tollovid entity
-Investor Relations firms are being engaged.
-Active discussions with Nasdaq. Strong support from existing Institutional investors
-Revenue coming in on Provista PCR testing, expect Q3
-Debt will convert to equity at uplist
Same old blah blah blah company not focused, investors just don't get how much we have going on.
(1)
(0)